12 completed, 8 recruiting, 8 terminated, 7 unknown. 17 Phase 2, 12 Phase 1, 5 Not applicable, 2 Phase 3, 1 Phase 4.
Follow Pleural Mesothelioma: new trials by email Literature Review of Pleural Mesothelioma trials Research Report on Pleural Mesothelioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Trial in Advanced Epithelioid Mesothelioma VT3989, gemcitabine, Vinorelbine - Pleural Mesothelioma, Mesothelioma | Phase 3 | Not yet recruiting | Vivace Therapeutics, Inc | 350 | 2026-12-01 | 2026-09-17 |
| Evaluation of Skin Tests in Biotherapy Allergies Drug skin tests (investigating hypersensitivity to a biotherapy) - Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms | Not applicable | Recruiting | University Hospital, Angers | 70 | 2026-06-17 | 2026-06-18 |
| A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors IDE892, IDE397 - NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC) | Phase 1 | Recruiting | IDEAYA Biosciences | 260 | 2026-03-04 | 2026-09-28 |
| The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma [68Ga]Ga-FAPI-46 PET/CT - Pleural Mesothelioma, Pleural Diseases | Phase 2 | Recruiting | Aalborg University Hospital | 70 | 2025-01-29 | 2025-07-03 |
| Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab - Pleural Mesothelioma | Phase 2 | Active not recruiting | Istituto Oncologico Veneto IRCCS | 41 | 2024-11-06 | 2026-01-13 |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 7 Hills Pharma, LLC | 126 | 2024-08-23 | 2026-04-13 |
| Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma Cadonilimab Combined with chemotherapy - Pleural Mesothelioma | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 59 | 2024-06-20 | 2024-05-16 |
| A Study of MT027 in Patients with Pleural Malignant Tumors MT027 cells suspension - Advanced Malignant Solid Tumor, Malignant Pleural Effusion | Phase 1 | Recruiting | Suzhou Maximum Bio-tech Co., Ltd. | 18 | 2024-05-15 | 2024-12-10 |
| Evaluation of Response by FLT PET in Mesothelioma FLT PET imaging - Pleural Mesothelioma, Treatment Response | Not applicable | Unknown | Ankara University | 25 | 2024-04-01 | 2024-05-16 |
| Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin - Pleural Mesothelioma | Phase 2 | Unknown | Sun Yat-sen University | 38 | 2023-11-01 | 2024-02-21 |
| TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO Lung Cancer, Non-small Cell, Small Cell Lung Cancer | Recruiting | University College, London | 600 | 2023-10-20 | 2026-07-13 | |
| TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study TTFields - Pleural Mesothelioma | Recruiting | NovoCure Ltd. | 198 | 2023-08-01 | 2025-08-22 | |
| INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP) Functional tests, Multi-omics analyses, Cytogenetics/ FISH - Acute Leukemia, Multiple Myeloma | Not applicable | Recruiting | Azienda Ospedaliero-Universitaria di Parma | 300 | 2023-05-31 | 2026-02-17 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers XmAb20717 - Microsatellite High Cancers, Peritoneal Mesothelioma | Phase 2 | Suspended | M.D. Anderson Cancer Center | 140 | 2022-08-05 | 2026-10-13 |
| Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA - Mesothelioma, Malignant, Gene Abnormality | Unknown | Hospices Civils de Lyon | 30 | 2022-02-11 | 2024-02-01 | |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) THOR-707, Pembrolizumab - Pleural Mesothelioma, Non-small Cell Lung Cancer | Phase 2 | Terminated | Sanofi | 106 | 2021-09-23 | 2025-10-02 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-30 |
| DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab - Mesothelioma, Pleural Mesothelioma | Phase 3 | Completed | PrECOG, LLC. | 214 | 2021-02-18 | 2026-10-22 |
| Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention Pleural interventions - Pleural Diseases, Pleural Mesothelioma | Unknown | University of Oxford | 2000 | 2020-09-01 | 2023-06-18 |
Showing 20 of 40. Sign in to see all of them.
Mesothelioma, Malignant (40) · Carcinoma, Non-Small-Cell Lung (6) · Colorectal Neoplasms (6) · Melanoma (6) · Mesothelioma (6) · Neoplasm Metastasis (6) · Ovarian Neoplasms (5) · Carcinoma, Renal Cell (4) · Neoplasms (4) · Pancreatic Neoplasms (4) · Pleural Effusion (4) · Stomach Neoplasms (4) · Urinary Bladder Neoplasms (4) · Carcinoma, Transitional Cell (3) · Esophageal Neoplasms (3)
Adenoma (40) · Neoplasms by Histologic Type (40) · Neoplasms by Site (40) · Neoplasms, Glandular and Epithelial (40) · Neoplasms, Mesothelial (40) · Respiratory Tract Diseases (40) · Respiratory Tract Neoplasms (40) · Thoracic Neoplasms (40) · Lung Diseases (39) · Lung Neoplasms (38) · Pleural Neoplasms (38) · Neoplasms (36) · Mesothelioma (34) · Carcinoma (10) · Female Urogenital Diseases (10)
Cisplatin (7) · Pemetrexed (5) · pembrolizumab (5) · Nivolumab (3) · durvalumab (3) · sodium thiosulfate (3) · Carboplatin (2) · Interleukin-2 (2) · Ipilimumab (2) · Anesthesia, General (1) · Cyclophosphamide (1) · Docetaxel (1) · Doxorubicin (1) · Drug Therapy (1) · Drugs, Generic (1)
Dana-Farber Cancer Institute (3) · PrECOG, LLC. (2) · University Health Network, Toronto (2) · 7 Hills Pharma, LLC (1) · Aalborg University Hospital (1) · Ankara University (1) · Azienda Ospedaliero-Universitaria di Parma (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Columbia University (1) · Henry Ford Health System (1) · Hospices Civils de Lyon (1) · IDEAYA Biosciences (1) · Istituto Oncologico Veneto IRCCS (1) · Italian Network for Tumor Biotherapy Foundation (1) · Kantonsspital Winterthur KSW (1)
United States (17) · Italy (7) · Australia (5) · France (5) · United Kingdom (5) · Spain (4) · Canada (3) · Switzerland (3) · Argentina (2) · China (2) · Denmark (2) · Egypt (2) · Germany (2) · Poland (2) · South Korea (2)
David J. Sugarbaker, MD (3) · Patrick Forde, MD (2) · Ahmed F Koraitim, MD (1) · Anna Nowak, MD (1) · Anu Gupta, MD (1) · Arash Yavari, MBBS (1) · Arvind Nageshwara Dasaru, MD (1) · Daniel H. Sterman, M.D. (1) · David M Svinarich, PhD (1) · Edward Chan, MD (1) · Galina Velikova (1) · Giulia Pasello, MD (1) · Hany H El Sayed, Professor (1) · Hedy Kindler, MD (1) · Helle Zacho, MD, DMSc (1)
PMID 34499875, PMID 29773326, PMID 30473706, PMID 33358660, PMID 33844995, PMID 34750557, PMID 36800443, PMID 42444902
2023 (1), P01CA066726 (1)